Gossamer Bio (NASDAQ:GOSS) Shares Surge as FDA Progress Highlights Path Forward; Cash Covenant Looms as Next Hurdle

Gossamer Bio shares hovered near $0.42 in premarket trading Tuesday, following a brutal 80% plunge the previous day after its flagship lung-disease therapy fell short in a late-stage trial. With the stock off about $1.71 from its earlier close, traders weighed a harder path to U.S. approval, despite some isolated positives in the data.